Prior immunogenicity to anti-TNF did not confer a significantly risk of immunogenicity to UST in a cohort of 152 IBD patients, as the majority of real-worlds patients have likely failed anti-TNF biologics (80). The gene discussed is TNF; the disease is inflammatory bowel disease.